Blood Products Advisory Committee; Cancellation

---
identifier: "/us/fr/2012-3199"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Blood Products Advisory Committee; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "2012-3199"
section_name: "Blood Products Advisory Committee; Cancellation"
positive_law: false
currency: "2012-02-13"
last_updated: "2012-02-13"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2012-3199"
document_type: "notice"
publication_date: "2012-02-13"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "77 FR 7588"
fr_volume: 77
docket_ids:
  - "Docket No. FDA-2012-N-0001"
fr_action: "Notice."
---


#  Blood Products Advisory Committee; Cancellation

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The meeting of the Blood Products Advisory Committee scheduled for February 29, 2012 is cancelled. This meeting was announced in the *Federal Register* of January 30, 2012 (77 FR 4567). FDA intends to convene at a future date a public scientific workshop to discuss the evaluation of possible new plasma products manufactured following storage at room temperature for up to 24 hours.

**FOR FURTHER INFORMATION CONTACT:**

Bryan Emery or Pearl Muckelvene,  Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, Contact 1-301-827-1277 or 1-301-827-1281, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.

Dated: February 7, 2012.

Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.